Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
LNJQTKgv43kYtXZr
Listen
